Abbott Files First Humira sBLA, AstraZeneca Seeks IV Nexium; More Filings
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott has kicked off its planned label expansion program for Humira with an Oct. 1 filing for an improved physical function claim in rheumatoid arthritis.
You may also be interested in...
Zetia/Zocor Combo User Fee In July 2004; Genentech Sees Avastin On Time
The user fee deadline for Merck/Schering-Plough’s Zetia/Zocor combination product for cholesterol reduction is July 24, 2004.
Abbott Humira
Abbott's lead project, TNF-alpha inhibitor Humira (adalimumab, D2E7), clears FDA Dec. 31 for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatics. Abbott is highlighting convenience of once-weekly dosing, efficacy in reducing structural joint damage and price to encourage switching RA patients from Amgen/Wyeth's Enbrel (etanercept) and J&J's Remicade (infliximab). Enbrel and Remicade carry more indications; Abbott plans to begin filing for five additional indications in 2004. Supply of the biologic is adequate, Abbott say
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011